Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Novartis AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Introduction: Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Clinical Trials

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Valsartan/Hydrochlorothiazide
Drug: HCTZ

First Posted Date: 2006-01-16

Last Posted Date: 2011-06-07

Lead Sponsor: Novartis

Target Recruit Count: 300

Registration Number: NCT00277472

Locations: 🇺🇸
Novartis, East Hanover, New Jersey, United States

Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures

Phase 4

Completed

Conditions: Epilepsy, Partial Seizures

First Posted Date: 2006-01-12

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis

Target Recruit Count: 60

Registration Number: NCT00275912

Locations: 🇷🇺
Regional Pediatric Clinical Hospital №1 EkaterinburgRegional Pediatric Clinical Hospital №1, Ekaterinburg, Russian Federation
🇷🇺
Moscow Scientific Research Institute of Pediatrics and Pediatric Surgery, Moscow, Russian Federation
🇷🇺
Russian State Medical University clinically based on Russian Pediatric Clinical Hospital, Moscow, Russian Federation

and more 2 locations

Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Phase 3

Completed

Conditions: Age Related Macular Degeneration

Interventions: Drug: Ranibizumab 0.5 mg - 3 times monthly, then quarterly
Drug: Ranibizumab 0.3 mg - 3 times monthly, then quarterly
Drug: Ranibizumab 0.3 mg monthly

First Posted Date: 2006-01-12

Last Posted Date: 2011-03-16

Lead Sponsor: Novartis

Target Recruit Count: 353

Registration Number: NCT00275821

Locations: 🇨🇭
Novartis, Basel, Switzerland

Safety and Efficacy of Oxcarbazepine Monotherapy in Adults With Partial Seizures

Phase 4

Completed

Conditions: Epilepsy, Partial Seizures

First Posted Date: 2006-01-12

Last Posted Date: 2007-11-30

Lead Sponsor: Novartis

Target Recruit Count: 80

Registration Number: NCT00275925

Locations: 🇷🇺
Epilepsy Department of the Moscow Research Institute of Psychiatry, Moscow, Russian Federation
🇷🇺
Neurology and Neurosurgery Department of the Moscow State Medico-stomatology University, Moscow, Russian Federation
🇷🇺
Neurology and Neurosurgery Department of the Russian State Medical University, Moscow, Russian Federation

and more 4 locations

Valsartan/Hydrochlorothiazide Combination in the Treatment of Severe Hypertension

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2006-01-09

Last Posted Date: 2011-11-08

Lead Sponsor: Novartis

Target Recruit Count: 607

Registration Number: NCT00273299

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

Phase 4

Completed

Conditions: Allergic Asthma

Interventions: Drug: Placebo
Drug: Omalizumab
Drug: Immunotherapy

First Posted Date: 2005-12-20

Last Posted Date: 2016-09-14

Lead Sponsor: Novartis

Target Recruit Count: 275

Registration Number: NCT00267202

Locations: 🇺🇸
Novartis, East Hanover, New Jersey, United States

Efficacy and Safety of Lumiracoxib

Phase 3

Completed

Conditions: Osteoarthritis

First Posted Date: 2005-12-20

Last Posted Date: 2012-05-21

Lead Sponsor: Novartis

Target Recruit Count: 330

Registration Number: NCT00267215

Locations: 🇩🇪
Novartis, Nuernberg, Germany

Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Omalizumab
Other: Optimized asthma therapy

First Posted Date: 2005-12-13

Last Posted Date: 2018-06-29

Lead Sponsor: Novartis

Target Recruit Count: 406

Registration Number: NCT00264849

Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2005-12-06

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis

Target Recruit Count: 693

Registration Number: NCT00262236

Locations: 🇨🇭
Novartis, Basel, Switzerland

A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure

Phase 3

Completed

Conditions: Hypertension

First Posted Date: 2005-12-02

Last Posted Date: 2011-11-08

Lead Sponsor: Novartis

Target Recruit Count: 641

Registration Number: NCT00260923

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy